Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients.
Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients.
复制标题
评估白介素-23/17轴在危重患病患者中的作用。
DOI：
10.3390/jpm11090891
复制
发表时间：
2021-09-07
影响因子：
--
通讯作者：
Kotanidou A
中科院分区：
文献类型：
--
作者：
Jahaj E;Vassiliou AG;Keskinidou C;Gallos P;Vrettou CS;Tsipilis S;Mastora Z;Orfanos SE;Dimopoulou I;Kotanidou A
研究假设白细胞介素（IL）-23/17轴在2019冠状病毒病（COVID-19）中的潜在作用。然而，迄今为止，尚未在重症COVID-19患者和重症非COVID-19患者之间比较IL-23和IL-17的水平。在重症COVID-19（N = 38）和重症非COVID-19（N = 34）患者（危重疾病严重程度相同）入住重症监护室（ICU）时测量IL-23和IL-17。重症非COVID-19患者在ICU入院时未发生败血症或感染性休克。入组患者既往均未接受过皮质类固醇。在我们的研究中，COVID-19患者的循环IL-17水平较高。更具体地说，重症COVID-19患者的水平为0.78（0.05-1.8）pg/mL，而重症非COVID-19患者为0.11（0.05-0.9）pg/mL（p = 0.04）。相比之下，组间IL-23水平相当。一组在专门的COVID-19诊所住院的患者（N = 16）也用于评估IL-17和IL-23水平与COVID-19严重程度的关系。非重症COVID-19患者的两种细胞因子水平均检测不到。我们的结果支持在严重COVID-19感染中抑制IL-17的概念。
Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admission to the intensive care unit (ICU) in critically ill COVID-19 (N = 38) and critically ill non-COVID-19 (N = 34) patients with an equal critical illness severity. Critically ill non-COVID-19 patients did not have sepsis or septic shock on ICU admission. None of the enrolled patients had previously received corticosteroids. In our study, circulating IL-17 levels were higher in the COVID-19 patients. More specifically, critically ill COVID-19 patients had levels of 0.78 (0.05–1.8) pg/mL compared to 0.11 (0.05–0.9) pg/mL in the critically ill non-COVID-19 patients (p = 0.04). In contrast, IL-23 levels were comparable between groups. A group of patients hospitalized in the specialized COVID-19 clinic (N = 16) was also used to evaluate IL-17 and IL-23 levels with respect to COVID-19 severity. Non-critically ill COVID-19 patients had undetectable levels of both cytokines. Our results support the notion of inhibiting IL-17 in critical COVID-19 infection.
登录
查看更多内容
影响因子：
3.8
作者：
Avdeev SN;Trushenko NV;Tsareva NA;Yaroshetskiy AI;Merzhoeva ZM;Nuralieva GS;Nekludova GV;Chikina SY;Gneusheva TY;Suvorova OA;Shmidt AE
通讯作者：
Shmidt AE
影响因子：
6
作者：
Martonik D;Parfieniuk-Kowerda A;Rogalska M;Flisiak R
通讯作者：
Flisiak R
影响因子：
3.4
作者：
Burgos-Blasco, Barbara;Guemes-Villahoz, Noemi;Maria Martinez-de-la-Casa, Jose
通讯作者：
Maria Martinez-de-la-Casa, Jose
影响因子：
3.8
作者：
Vassiliou, Alice G.;Mastora, Zafeiria;Kotanidou, Anastasia
通讯作者：
Kotanidou, Anastasia
影响因子：
2.3
作者：
Vassiliou, Alice G.;Dimopoulou, Ioanna;Kotanidou, Anastasia
通讯作者：
Kotanidou, Anastasia